Reproducing article published in PRNewswire circulated from New Jersey, USA
DSM Announces Marketing and Sales Alliance With Indoco
PARSIPPANY, N.J., Jan. 31, 2012 /PRNewswire/ -- Royal DSM N.V.,
(DSM KON: NYSE/Euronext) today announced the signing of an agreement
with Indoco Remedies Limited, Mumbai, India, for commercial cooperation for
eight Active Pharmaceutical Ingredients (APIs). The alliance came into effect
in January 2012.
In line with DSM and Indoco's strategy, this agreement
represents a step to forge an alliance to expand presence in markets across
the globe. The API's manufactured by Indoco and to be marketed and sold by
DSM are used in the production of pharmaceutical Finished Dosages. This alliance
will leverage Indoco's product development and cGMP (current Good Manufacturing
Practices) compliant manufacturing capabilities and DSM's market access.
In addition DSM will use its operation and quality systems to allow faster
growth in regulated markets. Alexander Wessels, President and Chief Executive
Officer, DSM Pharmaceutical Products (DPP) stated, "This is a step in our announced
strategy to accelerate growth via partnerships and expansion in Asia to build a
product portfolio along side our custom manufacturing operations, supplying access
to high demand treatments. It allows DPP to build a competence base in India." The
Indoco alliance is anchored in DSM's API business, DSM Pharma Chemicals,
headquartered in Austria.
Mr. Suresh G. Kare, Chairman & Managing Director, Indoco Remedies, commented,
"Today in the era of alliances and partnerships, organizations are coming together
to penetrate and capture a larger share of the potential opportunities in the market
place. Indoco is active in forging such alliances and this one with DSM is a step
in that direction. This alliance offers a great opportunity to expand our global
presence with a well established partner like DSM." Founded in 1947, Indoco Remedies
is one of the leading manufacturers of APIs and Finished Dosages in India for various
therapeutic classes. USDMFs (US Drug Master File), CoS (Certificate of Suitability
for European Pharmacopoeia) and DMFs ( Drug Master Files) have been filed by Indoco
for some products and Indoco has been seeking to expand supplies to markets across
the globe, including European and US generic and branded pharmaceutical companies.
DSM was preferred for this strategic alliance by Indoco based on the strength of
their longstanding pharmaceutical customer contacts and presence in markets worldwide
combined with their deep commitment to quality.
Indoco Remedies Limited
Established in the year 1947, Indoco Remedies is a global pharmaceutical company
with a presence across 80 countries. Under the leadership of Mr. Suresh G. Kare,
Chairman and Managing Director, Indoco Remedies is a USD 120 million turnover
organization employing about 4,000 people. Indoco has a strong brand portfolio
of 120 products in various therapeutic segments, including high growth life style
segments such as Anti-Infectives, Anti-Diabetics, Cardiovascular, Ophthalmology,
Dental Care, Pain Management and Respiratory. Top Indoco brands include Cyclopam,
Vepan, Febrex Plus, ATM, Sensodent–K, and Sensoform. Indoco has nine manufacturing
facilities for Formulations (Finished Dosage Forms) and Active Pharmaceutical
Ingredients (APIs) in India. Indoco also has a state-of-the-art research centre at
Navi Mumbai with over 200 scientists. With approval of its Finished Dosage facilities
by the US-FDA, Darmstadt-Germany, TGA Australia, MCC-South Africa and UK-MHRA,
Indoco Remedies has emerged as the most suitable partner and provider of Contract
Research and Manufacturing Services (CRAMS) to its customers globally.
For more details on Indoco you can visit www.indoco.com
DSM – Bright Science. Brighter Living.™
DSM Pharmaceutical Products is a Business Group of Royal DSM N.V. and is a global
science-based company active in health, nutrition and materials. By connecting its
unique competences in Life Sciences and Materials Sciences DSM is driving economic
prosperity, environmental progress and social advances to create sustainable value
for all stakeholders. DSM delivers innovative solutions that nourish, protect and
improve performance in global markets such as food and dietary supplements, personal
care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
DSM's 22,000 employees deliver annual net sales of about 9 billion euros.
The company is listed on NYSE Euronext.
More information can be found at
www.dsmpharmaceuticalproducts.com
and www.dsm.com
Forward-looking statements
This press release may contain forward-looking statements with respect to
DSM's future (financial) performance and position. Such statements are based
on current expectations, estimates and projections of DSM and information
currently available to the company. DSM cautions readers that such statements
involve certain risks and uncertainties that are difficult to predict and
therefore it should be understood that many factors can cause actual
performance and position to differ materially from these statements.
DSM has no obligation to update the statements contained in this press
release, unless required by law. The English language version of the press
release is leading.
|